Daily Alpha · Reddit
· Post-Market Alpha · by Buzzberg Research
Retail boards mixed dip buying with defensive income: traders added to AMD, NVDA and MU on weakness, Superstonk argued a GameStop re-rating toward $32-60, and income investors picked up Accenture, pipelines and I-Bond exposure.
Themes on this desk
AI-hardware dip buying
Across r/AMD_Stock, r/NVDA_Stock and r/stocks, posters added to beaten-down chips: one went all in on AMD at what he treated as the bottom, another called the NVDA selloff overdone, and a third bought MU, NVDA and NBIS; a separate AMD poste
Income and defensive rotation
Dividend boards lean defensive: ACN bought near lows with plans to add, new SCHD/F/MPLX/ET positions, and I-Bond demand expected to revive on higher variable and fixed rates.
India macro skepticism
Indian-market threads flag a flattening 5s10s curve as a headwind, argue Dixon Technologies falls on weak volumes and JV dilution, and debate Jio's roughly ₹10 lakh crore IPO valuation.
Highest engagement
by score · day changeIMF: South Korea's per-capita GDP passes Spain this year and Italy by 2028 on the chip boom
The post relays IMF projections that South Korea's per-capita GDP will top $43,500 this year and $50,000 by 2028, driven by a semiconductor export boom and an expected stronger won.
IMF: South Korea's Per-Capita GDP to Top $43,500 This Year, Passing Spain, $50,000 by 2028, Passing Italy The International Monetary
A concrete income dividend from the memory cycle landing outside the US, relevant to Korea exposure and semiconductor demand durability.
Watch Korean export data and the won; a memory downcycle would undercut the trajectory.
Source →Uber, Booking and AppLovin flagged as 'best buys' on cash flow and moats
The author is watching Uber, Booking and AppLovin as buys at current prices on solid free cash flow, low debt and strong moats, with AI/robotics seen as either risk or catalyst and AppLovin the speculative leg that must prove continued growth.
UBER / BOOKING / APPLOVIN Hello guys, I am watching these company and at this price I think they are
Shows value-oriented retail shopping for cash-generative platforms rather than adding more AI hardware risk.
Watch AppLovin's growth trajectory and any AI-driven disruption to these platforms' moats.
Source →Superstonk: Ryan Cohen is forcing a GameStop re-rating toward $32–60
The poster argues the recent move is Cohen forcing a re-rating of GameStop toward a $32–60 fair value based on P/E and $700M of annual operating income, with MOASS beginning once the ramp ignites.
Hot take. The price movement is just Ryan forcing a rerating on the company that should be vtrading between 32-60$
Captures how retail holders are anchoring GameStop on an operating turnaround rather than the legacy business, a flow factor into the next catalyst.
Watch GameStop's next operating update and whether the re-rating holds; a fade back toward pre-move levels invalidates.
Source →Copart called 'too easy' at 16x earnings with a duopoly and the ACV deal
The author argues Copart is undervalued at 16x earnings with high free-cash-flow margins, no debt, founder-aligned management, a duopoly position, and the ACV acquisition expanding it into the whole-car market.
Copart seems too easy here 16X earnings 26% free cash flow margin 22.5% EPS CAGR going back 10 years No
A concrete cash-flow value case outside crowded AI exposure, with the ACV integration as the swing factor.
Watch Copart's unit volumes and ACV integration progress in coming quarters; volume deterioration invalidates the value case.
Source →TeraWulf squeeze setup: rising short interest plus AI/HPC power contracts
The bullish thesis argues WULF's high and rising short interest combined with AI/HPC power contracts could force a squeeze near upcoming catalysts.
$WULF DD – The Shorts Are Getting CUKT and They Don’t Even Know It Yet TeraWulf ($WULF) is sitting on
Shows retail treating contracted power as the scarce AI asset, aligning with the session's power-constraint theme.
Watch Short-interest updates and TeraWulf's contract announcements; a catalyst passing without a squeeze invalidates.
Source →Most argued
by comments per upvoteAlpha Tau's ~$1.26B valuation already prices in trial success, fact-check argues
The fact-check argues the FDA approval timeline is unsupported and that Alpha Tau Medical's roughly $1.26B valuation already prices in a lot of success ahead of the ReSTART readout.
I think it's mostly about it being at $1.2B which is very high for a company with no revenue, so
A reminder that clinical-catalyst risk can be fully capitalized ahead of binary data, with the readout as the reset event.
Watch The ReSTART readout and any regulatory correspondence; positive data invalidates the skepticism.
Source →QIMC was a pump-and-dump that used shareholders as short cover, poster alleges
The author claims QIMC was a pump-and-dump where shareholders were used as short cover during a company raise, with the stock now below $0.40.
Qimc meltdown About a month ago, I had posted about feeling duped by QIMCs p&d, facilitated by an informal qimc
A cautionary data point on microcap promotion dynamics while speculative flows rotate.
Watch Any company or regulatory response to the allegations.
Source →